Rite Aid Corporation
) yesterday came up with mixed results for the first quarter of
fiscal 2015, wherein its top-line improved year over year but
profits declined steeply from the comparable year-ago quarter. This
made investors slightly cautious resulting in a 3.5% fall in the
company's share price during yesterday's trading session.
The company's earnings of 4 cents per share for the first
quarter declined 55.6% from the prior-year earnings of 9 cents
primarily due to high cost of drugs and lower reimbursement rate.
However, quarterly earnings were in line with the Zacks Consensus
Rite Aid's first-quarter revenues rose 2.7% year over year to
$6,465.5 million and surpassed the Zacks Consensus Estimate of
$6,430.0 million. Top-line growth was driven by improved
comparable-store sales (comps). Comps in the quarter rose 3.1% due
to rise in pharmacy sales.
During the quarter, pharmacy sales increased 4.6% despite a
negative impact of 143 basis points (bps) due to introduction of
new generic drugs. Additionally, prescriptions filled at comparable
stores increased 2.3% year over year. Prescription sales
constituted about 68.4% to total drugstore sales while third-party
prescription revenues accounted for 97.4% of the pharmacy sales.
However, Rite Aid's front-end sales remain flat year over year.
Rite Aid's FIFO gross profit decreased 1.6% year over year to
$1,804.5 million, while gross margin contracted 122 bps to 27.91%
primarily due to high drug prices. Selling, general and
administrative (SG&A) expenses rose 2.2% to $1,644.4 million
while as a percentage of sales it contracted 14 bps to 25.43%
primarily due to effective cost management.
Rite Aid's adjusted earnings before interest, taxes,
depreciation and amortization (EBITDA) decreased 18% year over year
to $282.6 million breaking the record of 13 straight quarters of
improved adjusted EBITDA. Moreover, as a percentage of sales, it
contracted 111 bps to 4.37% primarily due to lower reimbursement
rates along with higher salary and payroll expenses.
Balance Sheet & Cash Flow
At quarter-end, Rite Aid which competes with
China Nepstar Chain Drugstore Ltd.
) had cash and cash equivalents of $166.0 million and long-term
debt (excluding current maturities) of $5,519.6 million. The
company ended the quarter with $1.368 billion of liquidity. Rite
Aid had $351.0 million of outstanding debt under its $1.8 billion
senior secured credit facility and $88.0 million of outstanding
letters of credit.
During the first quarter, the company generated cash flow of
$239.7 million from operating activities and incurred capital
expenditure of nearly $179.2 million. For fiscal 2015, the company
expects capital expenditure of $525.0 million, out of which $225.0
million is anticipated to be deployed toward store remodeling while
$90.0 million will be spent on buying file.
Rite Aid stores continue to undergo renovation with 105 outlets
being remodeled in the quarter. Additionally, the company relocated
3 stores while it shut down 7 outlets during the quarter. At
quarter-end, the company completed wellness remodels at 1,325
stores representing 29% of total locations.
Looking ahead, for fiscal 2015, the company intends to open 1
outlet, relocate 19 stores and remodel 450 stores. As of May 31,
2014, Rite Aid operated 4,581 stores across 31 states and the
District of Columbia.
Reaffirms Fiscal 2015 Guidance
The company has reiterated its guidance for fiscal 2015, which
was updated on Jun 5, wherein, based on the projections for the
first quarter and anticipated reductions in generic purchase price
for the rest of the year, the company trimmed its adjusted EBITDA,
net income and earnings per share forecasts for fiscal 2015.
However, it retained its sales, comps and capital expenditure
targets for the year.
The company, which trails only
CVS Caremark Corp.
) in size, now expects adjusted EBITDA for fiscal 2015 to range
from $1.275-$1.350 billion compared with $1.325-$1.4 billion guided
earlier. Net income forecast for the fiscal year is slashed to
$298-$408 million range versus $313.0-$423.0 million expected
As a result, full year earnings per share are now estimated in
the range of 30-40 cents as against the earlier forecast of 31-42
cents. Currently, the Zacks Consensus Estimate for the fiscal is
pegged at 33 cents per share.
Rite Aid continues to expect sales for fiscal 2015 to range
between $26.0 billion and $26.5 billion, with comps growth in the
band of 2.5% to 4.5%.
At present, Rite Aid has a Zacks Rank #4 (Sell).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
RITE AID CORP (RAD): Free Stock Analysis Report
CVS CAREMARK CP (CVS): Free Stock Analysis
WALGREEN CO (WAG): Free Stock Analysis Report
CHINA NEPSTAR (NPD): Free Stock Analysis Report
To read this article on Zacks.com click here.